Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lemtrada 'Behaves Like Chemotherapy For MS' Suggests 5-Year Efficacy Data

This article was originally published in Scrip

Executive Summary

Around two thirds of patients on Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) need no additional treatment up to four years after the two courses of infusion that make up its standard treatment schedule, according to Genzyme's Mike Panzara, therapeutic area head of MS, neurology and ophthalmology.

You may also be interested in...

ECTRIMS 2016: Alemtuzumab Benefits Continue Six Years Post-Treatment

The continuing benefits of Sanofi’s multiple sclerosis therapy Lemtrada six years after two short courses bolster the case for its use early in the course of the disease.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts